Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JN55 | ISIN: FR0013341781 | Ticker-Symbol: 52C
Frankfurt
04.11.24
08:16 Uhr
3,810 Euro
-0,140
-3,54 %
Branche
Hardware
Aktienmarkt
Sonstige
1-Jahres-Chart
2CRSI SA Chart 1 Jahr
5-Tage-Chart
2CRSI SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,9204,16504.11.
Dow Jones News
241 Leser
Artikel bewerten:
(1)

2CRSi SA: Financial Results 2023/2024

DJ 2CRSi SA: Financial Results 2023/2024

2CRSi SA 
2CRSi SA: Financial Results 2023/2024 
04-Nov-2024 / 18:00 CET/CEST 
Dissemination of a French Regulatory News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 
Financial Results 2023/2024: 
 
12-Month Revenue Multiplied by 4.8 
12-Month EBITDA at EUR6.4M 
 
 
Strasbourg (France), October 31, 2024 - 2CRSi (ISIN: FR0013341781) publishes its financial results for the period from 
March 1, 2023, to June 30, 2024 (a 16-month fiscal year[1]). The company's individual and consolidated financial 
statements will be submitted for approval at the upcoming General Meeting on December 19, 2024. 
 
Revenue of EUR223M, Exceeding Revised Targets 
As announced in the press release dated July 25, 2024, 2CRSi achieved a revenue of EUR223M for the 2023/24 fiscal year, 
significantly surpassing the revised target of EUR190M set on May 2, 2024. This 16-month period includes revenue from 
Boston from March to June 2023. Excluding Boston's activities, 2CRSi's consolidated revenue for the 16 months stands at 
EUR178.9M. Focusing on a comparable 12-month period (from July 2023 to June 2024), revenue reached EUR167.6M, representing 
a substantial increase compared to the previous year's EUR34.7M (excluding Boston and for a 12-month period from March 
2022 to February 2023). 
 
Proforma Financials to Assess Operational Performance 
To evaluate its operational performance across its new business structure, given the unique 16-month fiscal period 
ending June 30, 2024, and the divestiture of the Boston group, along with a shift from IFRS to ANC standards (French 
GAAP), 2CRSi has chosen to present additional 12-month consolidated financials for March 2022 - February 2023 and July 
2023 - June 2024. These additional proforma financials exclude Boston's contributions for March to June 2023 and follow 
French GAAP for comparability. 
 
Proforma Results for 12 Months: Profitable Growth Momentum 
The proforma results reveal a return to profitability, with EBITDA reaching EUR6.3M from July 2023 to June 2024, 
representing 3.76% of revenue, exceeding 2CRSi's expectations. This improvement is attributed to significant growth in 
activity, along with tight control of operating expenses. 
In EURM         Consolidated Accounts 2022/23 (12 Consolidated Accounts 2023/24  Consolidated Accounts 2022/23 
            months) [2]           (12 months) [3]         (16 months) 
French GAAP 
Revenue        34,7               167,6              178,9 
Other Operating Income 5,1                3,1               1,5 
Total Operating Income 39,8               170,6              180,4 
Consumed Purchases   (25,9)              (149,1)             (156,0) 
Personnel Expenses   (10,3)              (9,1)              (12,5) 
Taxes         (0,3)               (0,3)              (0,4) 
Other Operating Costs (5,7)               (0,4)              (0,5) 
External Costs     (8,4)               (5,2)              (8,4) 
Total Operating Costs (50,6)              (164,2)             (177,8) 
EBITDA         (10,7)              6,4               2,5 
Depreciation & Amort. (2,8)               (2,1)              (4,1) 
EBIT          (13,5)              4,3               (1,5) 
Finance Costs/Income  (0,8)               (1,9)              (2,3) 
Exceptional Items   (1,0)               0,03               (2,9) 
Income Tax       0.7                (0.2)              0,02 
Net Income (Group)   (14,5)              2,4               (6,5) 

Growth Driven by Global Demand for AI Solutions

Supported by the surging global demand for AI solutions (servers and computing power for the Cloud), 80% of revenue was generated from AI-focused solutions equipped with Nvidia chips, establishing 2CRSi as a key partner of Nvidia.

Analysis of Key Expense Items and Net Profit

Material costs, covering components for new high-performance servers, reached EUR149.1M or 89% of proforma revenue for 12 months. Personnel costs were controlled at EUR9.1M (5.4%), with external costs tightly managed at EUR5.2M (3%). Financial costs were negative at EUR1.9M (1.1%).

After tax, the net profit is positive at EUR2.4M (1.4%).

Outlook: Clear Path for Growth and Profitability Enhancement

Since the end of 2023, 2CRSi has entered a new hyper-growth phase driven by its "Godì" server solutions. The strong demand for these AI-focused solutions has led to increased orders, setting the stage for a promising fiscal year ahead in terms of growth and profitability. In the coming months, 2CRSi's performance will benefit from:

- A robust order book and solid contract execution.

- The launch of new servers designed for dual-phase immersion (Atlas 1.8) and an advanced generation of "Godì" servers equipped with the latest Nvidia H200 AI chips.

- Expansion in data center infrastructure design and sales, supporting both equipment sales and recurring services, which will enhance profitability. Advanced discussions with major partners are underway to this end.

General Meeting Scheduled for December 19, 2024

The fiscal 2023/2024 accounts (a unique 16-month period) reviewed by the Board of Directors on the date of this press release will be submitted for shareholder approval at the General Meeting on December 19, 2024.

Schedule for 2023/2024 Annual Financial Report Publication

As of this date, the Group's auditors have conducted their audit procedures on the financial statements (individual and consolidated), and audit reports are in the finalization stage. 2CRSi expects to publish its Annual Financial Report, including signed audit reports, in early November 2024. Download link: https://investors.2crsi.com/wp-content/ uploads/2024/10/RFA-23-24-WIP.pdf (French language only)

About 2CRSi

Founded in Strasbourg, 2CRSi designs, produces, and sells high-performance, eco-responsible computing servers tailored to customer needs. The Group offers innovative solutions (computing, storage, and networking) in over 50 countries. 2CRSi has been listed on the regulated Euronext Paris market (ISIN: FR0013341781) since June 2018, and its shares transferred to Euronext Growth in November 2022.

More information: www.2crsi.com

Contacts 2CRSi

2CRSi 
          Seitosei.Actifin                               Seitosei.Actifin 
Jean-Philippe 
LLOBERA       Foucauld Charavay                              Michael Scholze 
Head of       Financial Communication                           Financial press relations 
Communication                                          michael.scholze@seitosei-actifin.com 
          foucauld.charavay@seitosei-actifin.comFoucauld.charavay@seitosei-actifin.com 
investors@2crsi.com                                       +33 156 88 11 14 
          +33 180 18 26 33 
+33 368 41 10 70 

-----------------------------------------------------------------------------------------------------------------------

[1] Reminder: Following the sale of Boston Limited in June 2023, the fiscal year-end was adjusted to June 30, as decided at the General Meeting held on November 30, 2023. The revenue covers a 16-month period and includes Boston Group's four-month contribution (March to June 2023), based on data provided by Boston's management.

As such, four distinct sets of financial statements are presented:

-- Statutory Accounts: 16 months from March 1, 2023, to June 30, 2024 (French GAAP)

-- Consolidated Accounts: 16 months from March 1, 2023, to June 30, 2024 (French GAAP, voluntary basis)

-- Consolidated Accounts (Excluding Boston): 12 months from July 1, 2023, to June 30, 2024 (French GAAP,excluding Boston, voluntary basis)

-- Consolidated Accounts: 12 months from March 1, 2022, to February 28, 2023 (French GAAP)

-- Consolidated Accounts (Excluding Boston): 12 months from March 1, 2022, to February 28, 2023 (FrenchGAAP, excluding Boston)

[2] Restated Figures Excluding Boston Limited Sale

[3] Covering the Period from 07/01/2023 to 06/30/2024

-----------------------------------------------------------------------------------------------------------------------

Regulatory filing PDF file File: Financial Results 2023/2024

=---------------------------------------------------------------------- 
Language:    English 
Company:     2CRSi SA 
         32, rue Jacobi-Netter 
         67200 Strasbourg 
         France 
Phone:      +33 3 68 41 10 70 
E-mail:     investors@2crsi.com 
Internet:    www.2crsi.com 
ISIN:      FR0013341781 
Euronext Ticker: AL2SI 
AMF Category:  Inside information / News release on accounts, results 
EQS News ID:   2022081 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------ 

2022081 04-Nov-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2022081&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

November 04, 2024 12:00 ET (17:00 GMT)

© 2024 Dow Jones News
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.